ArticleSmall (Weinheim an der Bergstrasse, Germany)2024
Orthogonal Design of Experiments for Engineering of Lipid Nanoparticles for mRNA Delivery to the Placenta.
Article in Small (Weinheim an der Bergstrasse, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 34 citations in OpenAlex.
- Enhancing Lipid Nanoparticle-Mediated Circular RNA and mRNA Expression in the Placenta through Inhibition of IFNAR-JAK-STAT Signaling.Nano letters · 2026Article
- Nanotechnology-enabled precision strategies for bladder cancer: from in vitro diagnostics to in vivo therapy.Journal of nanobiotechnology · 2026Review
- The RNA delivery dilemma-lipid versus polymer nanoparticle platforms.Drug delivery and translational research · 2026Article
- Empowering women's health with miRNA-integrated nanochemical approaches: from reproductive health to cancer care.RSC advances · 2026Review
- Investigating the impact of hypoxia and syncytialization on lipid nanoparticle-mediated mRNA delivery to placental cells.Bioengineering & translational medicine · 2026Article
- Examining the effect of lipid nanoparticle elasticity on endocytosis and mRNA delivery to cancer cells.Med-X · 2026Article
- FABP4 as an immunometabolic hub in preeclampsia: from maternal-fetal interface to systemic inflammation.Frontiers in immunology · 2026Review
- Targeted nanoparticles for placenta-specific drug delivery in pregnant rhesus macaques.Theranostics · 2026Article
- Nano-Enabled Therapeutics: Novel Strategies for Preeclampsia Treatment.International journal of nanomedicine · 2026Review
- Article
- Nanotechnology strategies for endometrium health: Are we on the right track?Bioactive materials · 2025Review
- Therapeutic nanoparticle safety in pregnancy: Bridging knowledge gaps with environmental insights and a translational roadmap.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
- CGKRK-targeted lipid nanoparticles enhanceiScience · 2025Article
- Optimization of a Dissolvable Lipid Nanoparticle Microneedle Formulation for mRNA Delivery Using Design of Experiments.ACS applied materials & interfaces · 2025Article
- Flow cytometric analysis of the murine placenta to evaluate nanoparticle platforms during pregnancy.Placenta · 2025Article
- Probing the Role of Lipid Nanoparticle Elasticity on mRNA Delivery to the Placenta.Nano letters · 2025Article
- A Chemoinformatic-Guided Synthesis of a Spleen-Expressing mRNA Lipid Nanoparticle Platform.Bioconjugate chemistry · 2025Article
- Article
- Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length.Journal of biomedical materials research. Part A · 2024Article
- In utero delivery of targeted ionizable lipid nanoparticles facilitates in vivo gene editing of hematopoietic stem cells.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
During healthy pregnancy, the placenta develops to allow for exchange of nutrients and oxygen between the mother and the fetus. However, placental dysregulation can lead to several pregnancy disorders, such as preeclampsia and fetal growth restriction. Recently, lipid nanoparticle (LNP)-mediated delivery of messenger RNA (mRNA) has been explored as a promising approach to treat these disorders. Here, iterative libraries of LNPs with varied excipient molar ratios are screened in vitro for enhanced mRNA delivery to placental cells with minimal cytotoxicity when compared to an LNP formulation with a standard excipient molar ratio. LNP C5, the top formulation identified by these screens, demonstrates a fourfold increase in mRNA delivery in vitro compared to the standard formulation. Intravenous administration of LNP C5 to pregnant mice achieves improved in vivo placental mRNA delivery compared to the standard formulation and mediates mRNA delivery to placental trophoblasts, endothelial cells, and immune cells. These results identify LNP C5 as a promising optimized LNP formulation for placental mRNA delivery and further validates the design of experiments strategy for LNP excipient optimization to enhance mRNA delivery to cell types and organs of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.